Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Significance: Immune checkpoint therapies have garnered significant attention due to their ability to induce dramatic clinical responses in patients with various solid tumor malignancies, including prostate cancer. However, these therapeutic agents often elicit immune-related adverse events (irAEs) that may result in substantial morbidity. Early intervention can markedly reduce the severity of the irAEs, but biomarkers that allow for their early detection and guide their management are lacking. Based on peripheral blood samples collected longitudinally in two prostate cancer clinical trials, we propose CD8 T-cell clonal expansion within the systemic circulation as a potential correlative biomarker of immune-related adverse events that occur with ipilimumab therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Contrary to that observed in response to viral infections and irAEs [20], the immune recovery following TGN1412-induced CRS was predominantly a CD4+ T-cell response.”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Autoimmune colitis, vitiligo, and autoantibody production are now included in CTCAE grading of irAEs due to immunotherapy [1, 4, 6, 20, 22, 34].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The relatively few naïve T-cells during early reconstitution is consistent with programmed recovery in patients following chemotherapy [39, 40], immune checkpoint blockade [20, 24], or after infection [41, 42].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredIn the citing paper
“as has early clonal expansion of large numbers of CD8+ T cells (Subudhi et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Subudhi et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 2×
“Immune checkpoint therapies are expanding their clinical indications from melanoma to other solid tumors (5, 7) and even hematological diseases such as refractory Hodgkin’s lymphoma (23).”
BackgroundNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“Ipilimumab, nivolumab, and pembrolizumab are immune checkpoint therapies that induce durable antitumor responses and improve survival in melanoma (1–4), nonsmall cell lung cancer (NSLC) (5, 6), and renal cell carcinoma (RCC) (7).”
BackgroundCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“Based on published data that clonal expansion of T cells in tumor tissues, which are likely tumor reactive, may predict for clinical benefit with immune checkpoint therapy (15), we hypothesized that clonal expansion of T cells in the systemic circulation, which are likely to be reactive against self-antigens, may corr…”
BackgroundSelf-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 2×
“Immune checkpoint therapies are expanding their clinical indications from melanoma to other solid tumors (5, 7) and even hematological diseases such as refractory Hodgkin’s lymphoma (23).”
BackgroundSelf-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“In a phase III study, ∼60% of ipilimumabtreated men with CRPC experienced irAEs, of which about 25% were grade 3–4 toxicities (12), which are frequencies similar to those observed with ipilimumab monotherapy in advanced melanoma patients (1, 2, 14).”
Background
Cited by
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citationHallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationCTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citationChesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7379 · Cited by 631
“Prior surgery 93 (95) 89 (89) Prior anticancer therapy† 25 (26) 29 (29) Radiotherapy 12 (12) 13 (13) Immunotherapy 10 (10) 16 (16) PD-1 inhibitors 2 (2) 3 (3) Chemotherapy 4 (4) 4 (4) Targeted small molecules 2 (2) 0 (0) BRAF inhibitors 2 (2) 0 (0) MEK inhibitors 1 (1) 0 (0) Biochemotherapy 2 (2) 1 (1) Isolated limb p…”
Metadata
- Authors
- Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., Emerson, R. O., Yusko, E., Vignali, M., Robins, H. S., Sun, J., Allison, J. P., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Adaptive Biotechnologies (United States) (US)
- Fred Hutch Cancer Center (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-10-03
- Volume
- 113
- Issue
- 42
- Pages
- 11919-11924
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5081579
- OpenAlex
- W2529299484
- Cited by
- 226
- References
- 32
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 16 · 2023: 25 · 2022: 39 · 2021: 35 · 2020: 30 · 2019: 18 · 2018: 22 · 2017: 13
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP120108)
- HHS | NIH | National Cancer Institute (CA1633793, CA088084, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, immune-related adverse events, CD8+ T cells, T cell clonal expansion, immune checkpoint inhibitors, metastatic prostate cancer, androgen deprivation therapy, biomarkers
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols, Disease Susceptibility, Humans, Male, Middle Aged, Prostatic Neoplasms, Severity of Illness Index, Biomarkers, T-Lymphocyte Subsets, Treatment Outcome, Clinical Trials, Phase II as Topic, CD8-Positive T-Lymphocytes, Lymphocyte Count, Clonal Evolution, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. https://app.cochat.ai/papers/10.1073/pnas.1611421113
- The paper
- Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., Emerson, R. O., Yusko, E., Vignali, M., Robins, H. S., Sun, J., Allison, J. P., & Sharma, P. (2016). Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1611421113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.